The Cambridge microbiome biotech closed its Series C, led by British Business Bank, to advance oral candidate MB310 into a Phase 2 ulcerative colitis study.

The CHMP has recommended talquetamab plus daratumumab for relapsed/refractory myeloma from second line, backed by Phase 3 MonumenTAL-3 data.

The joint venture will build an international network of industrial At-211 production sites, starting in Nantes in 2028, to supply targeted alpha therapy programmes.

Samsung Health's October update lowers the sleep coaching activation threshold and adds weekly adaptive guidance, plus expanded running levels and Strava route

LB2501, designed to generate CD19/CD20 CAR-T cells inside the patient without lymphodepletion, is the first dual-targeting in vivo CAR-T to clear

Satralizumab becomes the first subcutaneous at-home treatment for TED, backed by Phase III data showing significant reductions in proptosis and diplopia.

IBA secured a 12-unit Cyclone KIUBE 300 order to build a national PET radioisotope network in the US, with capacity configured for fluorine-18

Edesa's anti-CXCL10 antibody EB06 can now enrol US patients, with topline data from the 80-person trial expected in Q4 2027.

Eclipse Life Sciences said its biodegradable intravitreal implant met its primary safety endpoint and showed superior visual and anatomical outcomes versus Ozurdex at 24

The FDA has accepted Aquestive's resubmitted NDA for sublingual anaphylaxis film Anaphylm, setting a review deadline of 16 March 2027.

Phase 2b subset data in 24 relapsed/refractory Waldenström patients showed deep, durable responses, with a Phase 3 trial and FDA NDA filing both targeted

Anavex Life Sciences can now open a Phase 2a trial of blarcamesine in Fragile X syndrome, giving it open INDs across all three core CNS